IMRT中OAR和靶区相交体积与其吸收剂量间关系研究

doi:10.3760/cma.j.issn.1004-4221.2017.02.014

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (912 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To explore the relationship between the overlap volume of organ at risk (OAR) and target (V_overlap) and the mean dose to OAR (D_mOAR) in intensity-modulated radiotherapy (IMRT). Methods Fifty randomly selected patients undergoing IMRT for nasopharyngeal carcinoma (NPC) and an equal number of patients undergoing radical IMRT for cervical cancer in our hospital were enrolled as subjects. The relationship between V_overlap and D_mOAR in IMRT was analyzed. The Matlab software was used to generate function to fit the relationship between V_overlap and D_mOAR for different OARs. Results The V_overlap varied among patients with NPC or cervical cancer. The ratio of V_overlap to the volume of OAR (V_OAR) was positively correlated with the ratio of D_mOAR to the prescribed dose (D_p)(all P=0.01). A function was generated to fit the correlation between V_overlap/V_OAR ratio and D_mOAR/D_p ratio. Conclusions In IMRT, patients have different V_overlap/V_OAR ratios due to varied target volume, disease stages, OAR filling status, and OAR volume. As criteria for plan verification, a specific D_mOAR value for each OAR should be calculated before radiotherapy planning based on the corresponding correlation function and the V_overlap/V_OAR ratio with a fixed dose prescription. It can be used to reduce the subjective influence on the optimization of radiotherapy planning.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Pang Haowen
	Sun Xiaoyang
	Yang Bo
	Shi Xiangxiang
	Tang Tao
	Wu Jingbo

Key words： Radiotherapy Computer-assisted Organs at risk Correlationship

Received: 14 December 2015

Corresponding Authors: Sun Xiaoyang,Email:sunxy0611@126.com

Cite this article:

Pang Haowen,Sun Xiaoyang,Yang Bo et al. Relationship between the overlap volume of organ at risk and target and the dose to organ at risk in intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(2): 187-191.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.02.014 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I2/187

[1] Fang FM,Chien CY,Tsai WL,et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs.intensity-modulated radiotherapy-a longitudinal study[J].Int J Radiat Oncol Biol Phys,2008,72(2):356-364.DOI:10.1016/j.ijrobp.2007.12.054.
[2] Lin SJ,Pan JJ,Han L,et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series[J].Int J Radiat Oncol Biol Phys,2009,75(4):1071-1078.DOI:10.1016/j.ijrobp.2008.12.015.
[3] Wong FCS,Ng AWY,Lee VHF,et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2010,76(1):138-145.DOI:10.1016/j.ijrobp.2009.01.084.
[4] Lee AWM,Lau KY,Hung WM,et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma[J].Radiother Oncol,2008,87(2):204-210.DOI:10.1016/j.radonc.2008.02.003.
[5] Mell LK,Roeske JC,Mundt AJ.A survey of intensity-modulated radiation therapy use in the United States[J].Cancer,2003,98:204-211.DOI:10.1002/cncr.11489.
[6] Roeske JC,Lujan A,Rotmensch J,et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies[J].Int J Radiat Oncol Biol Phys,2000,48(5):1613-1621.DOI:10.1016/S0360-3016(00)00771-9.
[7] Chen MF,Tseng CJ,Tseng CC,et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy:comparison with conventional radiotherapy[J].Int J Radiat Oncol Biol Phys,2007,67(5):1438-1444.DOI:10.1016/j.ijrobp.2006.11.005.
[8] 中国鼻咽癌临床分期工作委员会.2010鼻咽癌IMRT靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.Working committee for the clinical stage nasopharyngeal carcinoma (NPC) in China.2010 expert consensus of nasopharyngeal carcinoma IMRT target and dosage design[J].Chin J Radiat Oncol,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.
[9] Radiation Therapy Oncology Group. A phase Ⅱ study of concurrent chemoradiotherapy using three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT)+ Bevacizumab (BV) for locally or regionally advanced nasopharyngeal cancer. RTOG 0615 2011-03-05][DB/OL].http://www.rtog.org/News/tabid/72/articleType/ArticleView/articleId/30/RTOG-0615-trial-results-show-the-spread-of-nasopharyngeal-cancer-is-reduced-by-bevacizumab.aspx.
[10] Radiation Therapy Oncology Group. A phase Ⅱ study of intensity modulated radiation therapy (IMRT)+/-chemotherapy for nasopharyngeal cancer. RTOG 0225[2011-03-05][DB/OL]. http://ascopubs.org/doi/full/101200/JCO.2008.19.9109.
[11] Hunt MA,Jackson A,Narayana A,et al. Geometric factors influencing dosimetric sparing of the parotid glands using IMRT[J].Int J Radiat Oncol Biol Phys,2006,66(1):296-304.DOI:10.1016/j.ijrobp.2006.05.028.
[12] Moore KL,Brame RS,Low DA,et al. Experience-based quality control of clinical intensity-modulated radiotherapy planning[J].Int J Radiat Oncol Biol Phys,2011,81(2):545-551.DOI:10.1016/j.ijrobp.2010.11.030.
[13] Lian J,Yuan LL,Ge YR,et al. Modeling the dosimetry of organ-at-risk in head and neck IMRT planning:an intertechnique and interinstitutional study[J].Med Phys,2013,40(12):121704.DOI:10.1118/1.4828788.
[14] Zhu XF,Ge YR,Li TR,et al. A planning quality evaluation tool for prostate adaptive IMRT based on machine learning[J].Med Phys,2011,38(2):719-726.DOI:10.1118/1.3539749.
[15] Appenzoller LM,Michalski JM,Thorstad WL,et al. Predicting dose-volume histograms for organs-at-risk in IMRT planning[J].Med Phys,2011,39(12):7446-7461.DOI:10.1118/1.4761864.